Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

about

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

Item

http://www.wikidata.org/entity/Q37638997

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@en

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@nl

type

Item

label

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@en

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@nl

prefLabel

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@en

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@nl

P1476

Review of effect of prescription omega-3 fatty acids on body weight. Commentary.

@en

P2093

Carl J Lavie

http://www.w3.org/2001/XMLSchema#string

P2860

Omega-3 polyunsaturated fatty acids and cardiovascular diseases.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Omega-3 fatty acids for cardioprotection.

Importance and management of dyslipidemia in the metabolic syndrome.

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.

Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.

Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?

Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.

P304

200-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2009.11.2089

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19940431

http://www.w3.org/2001/XMLSchema#string

P921

fatty acid